Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23129602 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Condition: Hypercholesterolemia, Familial
Interventions: Biological: evolocumab (AMG 145);   Other: PLACEBO

Indicates status has not been verified in more than two years